Clinical Trial Update: A Phase I, Open-label, Multicenter, Dose-Escalating Study to Evaluate the Safety and Tolerability of KH658 Gene Therapy in Participants With Neovascular Age-related Macular Degeneration [Phase 1]

View source ↗

Summary

Phase I, open-label, multicenter, dose-escalation study evaluating the safety and tolerability of KH658 gene therapy in participants with neovascular age-relate…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• KH658 gene therapy

Snippet

Sponsor: Chengdu Origen Biotechnology Co., Ltd. | Conditions: Age-Related Macular Degeneration | Phase 1 | Status: ACTIVE_NOT_RECRUITING